The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | STARTER-NET: everolimus + lanreotide for gastroenteropancreatic neuroendocrine tumor
Susumu Hijioka, MD, PhD, National Cancer Center, Tokyo, Japan, and Nobumasa Mizuno, MD, PhD, Aichi Cancer Center Hospital, Nagoya, Japan, present findings on the efficacy of combining everolimus with lanreotide in treating gastroenteropancreatic neuroendocrine tumor (GEP-NET), a type of neuroendocrine tumor. Dr Hijoka highlights that this combination therapy significantly prolonged progression-free survival (PFS) and was well-tolerated, with a hazard ratio of 0.74, suggesting consistency in PFS and overall survival (OS) between the two arms. This study suggests that everolimus plus lanreotide can be a new standard first-line treatment for patients with GEP-NET, particularly those with non-functioning tumors and poor prognostic factors, paving the way for future trials to broaden the indication to more aggressive cases. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
